Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET

Moleculin Biotech (Nasdaq: MBRX) has announced a webcast presentation on August 6, 2024, at 8:30 AM ET to discuss plans for its MIRACLE Phase 3 pivotal trial.

Rhea-AI Summary

Moleculin Biotech (Nasdaq: MBRX) has announced a webcast presentation on August 6, 2024, at 8:30 AM ET to discuss plans for its MIRACLE Phase 3 pivotal trial. The trial will evaluate Annamycin in combination with Cytarabine (AnnAraC) for treating AML patients who are refractory to or relapsed after induction therapy. This global trial, including US sites, marks a significant step in Moleculin's clinical development program.

The presentation will feature Walter Klemp, CEO, Dr. Paul Waymack, Senior Chief Medical Officer, and Dr. Michael Andreeff from MD Anderson Cancer Center. Investors can access the webcast via conference call or the company's website.

Positive

• Advancement to Phase 3 pivotal trial for AnnAraC in R/R AML treatment
• Global trial scope, including US sites
• Participation of renowned experts in the webcast presentation

Negative

• None.

Argus Session date unavailable

-6.95% session move Open Argus

Details

News Market Reaction – MBRX

The recorded move for MBRX in the trading session of this news was -6.95%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, Aug. 5, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), Phase 3 clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it will host a corporate update webcast presentation on Tuesday, August 6, 2024 at 8:30 AM ET to discuss its recently announced plans to advance Annamycin in combination with Cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred to as "AnnAraC") to a Phase 3 pivotal trial for the treatment of AML patients who are refractory to or relapsed after induction therapy (R/R AML). This Phase 3 "MIRACLE" trial (derived from Moleculin R/R AML AnnAraC Clinical Evaluation) will be a global trial, including sites in the US.

For the webcast presentation, Walter Klemp, Chairman and Chief Executive Officer, and Dr. Paul Waymack, Senior Chief Medical Officer of Moleculin will be joined by Michael Andreeff, MD, PhD, Professor of Medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.

Interested participants and investors may access the webcast presentation via conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call or by clicking here. The live audio webcast will be accessible on the Events page of the Investors section of the Moleculin website, moleculin.com, and will be archived for 90 days.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-to-host-webcast-presentation-to-discuss-recently-announced-plans-for-miracle-phase-3-pivotal-trial-tuesday-august-6-2024-at-830-am-et-302213970.html

SOURCE Moleculin Biotech, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the MIRACLE Phase 3 trial for Moleculin Biotech (MBRX)?

The MIRACLE Phase 3 trial is Moleculin's pivotal study evaluating Annamycin in combination with Cytarabine (AnnAraC) for the treatment of AML patients who are refractory to or relapsed after induction therapy.

When is Moleculin Biotech (MBRX) hosting its webcast presentation on the MIRACLE trial?

Moleculin Biotech is hosting the webcast presentation on Tuesday, August 6, 2024, at 8:30 AM ET.

Who will be presenting at Moleculin Biotech's (MBRX) MIRACLE trial webcast?

The presenters include Walter Klemp (CEO), Dr. Paul Waymack (Senior Chief Medical Officer), and Dr. Michael Andreeff from MD Anderson Cancer Center.

How can investors access Moleculin Biotech's (MBRX) MIRACLE trial webcast?

Investors can access the webcast via conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international), or through the Events page on Moleculin's website.